Telomir Pharmaceuticals Advances Telomere Research, Seeks Strategic Partnerships at BIO 2025
TL;DR
Telomir Pharmaceuticals to explore licensing, M&A, and collaborations at BIO International Convention 2025, gaining competitive edge.
Telomir-1, a small molecule by Telomir Pharma, aims to elongate telomeres and treat various diseases with novel clinical endpoints.
Telomir Pharma's Telomir-1 seeks FDA guidance for accelerated development to promote longevity and improve quality of life for humans and animals.
Telomir Pharma's participation in BIO International Convention 2025 highlights innovative approach to addressing degenerative and age-related diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
Telomir Pharmaceuticals is poised to accelerate its longevity research by pursuing strategic partnerships at the upcoming BIO International Convention in Boston. The company will leverage the conference's BIO One-on-One Partnering platform to explore potential licensing, mergers and acquisitions, and collaborative opportunities for its lead candidate, Telomir-1.
The small molecule therapeutic targets telomere elongation, a critical mechanism in addressing age-related cellular degradation. Preclinical data suggest broad therapeutic potential across multiple disease areas, including rare genetic conditions like Progeria and Werner's syndrome, as well as more prevalent health challenges such as Type 2 diabetes, aggressive prostate cancer, and macular degeneration.
Telomir plans to submit an Investigational New Drug (IND) application by the end of the year, with expectations of initiating first-in-human clinical trials in the first half of 2026. The company is actively seeking FDA guidance on developing novel clinical endpoints to potentially expedite the development pathway.
The research focuses on telomeres, protective DNA sequences at chromosome ends that naturally shorten with age. By developing a molecule capable of elongating these telomeres, Telomir aims to potentially slow or reverse core aging mechanisms, representing a significant advancement in longevity science for both human and animal health.
Curated from InvestorBrandNetwork (IBN)
